Resources

Publications

Filter Publications

Product



Year

Cost-Effectiveness of an Oral Cholate Challenge Test for the Management of Patients at Risk for Large Esophageal Varices

Shailesh Chavan, Michael P. McRae, Kelly R. Pitts, Gregory T. Everson | Research Article | published 22 November 2024 PLOS ONE

HepQuant DuO, HepQuant SHUNT

Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.

Mitchell Shiffman, K. Rajender Reddy, Michael, D. Leise3, Kamran Qureshi, Alastair D. Smith, Steve Helmke, John Kittelson, Michael P. McRae, Joanne C. Imperial, Gregory T. Everson, the SHUNT-V Investigators | Alimentary Pharmacology & Therapeutics, 2024; 0:1–13

HepQuant DuO, HepQuant SHUNT

A Validated LC-MS/MS Assay for the Quantitation of Cholate Isotopes in Human Serum

Steve M. Helmke, Michael P. McRae, Uwe Christians, Touraj Shokati, Gregory T. Everson | The Journal of Applied Laboratory Medicine 2024 Aug 16

HepQuant DuO

The Oral Cholate Challenge Test Quantifies Risk for Liver-Related Clinical Outcomes in Primary Sclerosing Cholangitis

Steve Helmke, John Kittelson, Joanne Imperial, Michael McRae, Gregory T. Everson | Gastro Hep Advances 2024

HepQuant DuO

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors’ reply

Tarek Hassanein, Andrew P. Keaveny, Parvez Mantry, Alastair D. Smith, Michael P. McRae, John Kittelson, Steve Helmke, Gregory T. Everson, for the SHUNT-V Investigators | Aliment Pharmacol Ther 2024

HepQuant DuO

Scientific Research: Posters & Presentations

February 2023

Fourth Annual HCC-TAG Conference

Huntington Beach, CA

November 2022

Obesity & NASH Drug Development Summit

Boston, MA

November 2022

AASLD – The Liver Meeting 2022

Poster of Distinction: The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population 

Maintenance Therapy with GLP-1 Receptor Agonists Does Not Impact the​ Clearance of Orally Administered Isotopes of Unconjugated Cholate

Cost-Effectiveness of the HepQuant DuO Test for the Management of Patients at Risk for Large Esophageal Varices

Poster of Distinction: Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO) 

Poster of Distinction: Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model  

The Oral Cholate Challenge Test Identifies the MASH Patients with ≥F3 Fibrosis with Greatest Hepatic Impairment Who Show the Most Benefit from Short-term Rencofilstat Therapy

SEE ALL